HER2 Support Group Forums - View Single Post

Lani · 08-31-2013, 11:40 AM

Anticancer Drugs. 2011 Nov 29. [Epub ahead of print]
Exploratory predictive and prognostic factors in advanced breast cancer treated
with metronomic chemotherapy.
Miscoria M, Tonetto F, Deroma L, Machin P, Loreto CD, Driol P, Minisini AM, Russo S, Andreetta C, Mansutti M, Damante
G, Fasola G, Puglisi F.
aDepartment of Oncology bRegional Coordination Centre of Rare Diseases cDepartment of Pathology dDepartment of Genetics,
University of Udine, Udine, Italy.
Abstract
The aim of the present study is to evaluate the clinical and biological factors (including markers of angiogenesis) as
potential predictors of prognosis and benefit from metronomic therapy in patients with advanced breast cancer (ABC).
Recent data suggest antiangiogenic activity of metronomic therapy. The study population included 62 patients with
pretreated ABC who received cyclophosphamide and methotrexate orally. Tumour samples were analysed by
immunohistochemistry for HER2, Ki-67, thymidine phosphorylase (TP), vascular endothelial growth factor and vascular
endothelial growth factor receptor. The results from immunohistochemical analysis and clinico-pathological variables were
studied to test their potential association with benefit from metronomic therapy. The median overall survival, progressionfree
survival and survival postprogression were 7.1 (range 0.2-38.3), 2.6 (range 0.2-28.9) and 3 (range 0-34.2) months,
respectively. Among the clinical variables, age, performance status and previous therapy with taxanes were significantly
associated with outcomes. Among the molecular markers, TP was found to be associated with progression-free survival.
Metronomic therapy is an effective choice for ABC. Young women with a more indolent disease had the greatest benefit
from this treatment. TP tumour expression might aid decision making but these findings must be confirmed in larger
prospective, properly designed studies.
PMID: 22129512 [PubMed - as supplied by publisher]

08-31-2013, 11:40 AM	#27
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Re: metronomic chemo Anticancer Drugs. 2011 Nov 29. [Epub ahead of print] Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. Miscoria M, Tonetto F, Deroma L, Machin P, Loreto CD, Driol P, Minisini AM, Russo S, Andreetta C, Mansutti M, Damante G, Fasola G, Puglisi F. aDepartment of Oncology bRegional Coordination Centre of Rare Diseases cDepartment of Pathology dDepartment of Genetics, University of Udine, Udine, Italy. Abstract The aim of the present study is to evaluate the clinical and biological factors (including markers of angiogenesis) as potential predictors of prognosis and benefit from metronomic therapy in patients with advanced breast cancer (ABC). Recent data suggest antiangiogenic activity of metronomic therapy. The study population included 62 patients with pretreated ABC who received cyclophosphamide and methotrexate orally. Tumour samples were analysed by immunohistochemistry for HER2, Ki-67, thymidine phosphorylase (TP), vascular endothelial growth factor and vascular endothelial growth factor receptor. The results from immunohistochemical analysis and clinico-pathological variables were studied to test their potential association with benefit from metronomic therapy. The median overall survival, progressionfree survival and survival postprogression were 7.1 (range 0.2-38.3), 2.6 (range 0.2-28.9) and 3 (range 0-34.2) months, respectively. Among the clinical variables, age, performance status and previous therapy with taxanes were significantly associated with outcomes. Among the molecular markers, TP was found to be associated with progression-free survival. Metronomic therapy is an effective choice for ABC. Young women with a more indolent disease had the greatest benefit from this treatment. TP tumour expression might aid decision making but these findings must be confirmed in larger prospective, properly designed studies. PMID: 22129512 [PubMed - as supplied by publisher]